Spectrum Pharmaceuticals (SPPI) revealed updated data from its Phase 2 study of poziotinib Tuesday morning in lung cancer patients. "In the first 11 patients, the confirmed objective response rate was 64%," said John Heymach, M.D., Ph.D.
from RTT - Before the Bell https://ift.tt/2qpg9Dd
via IFTTT
No comments:
Post a Comment